Cargando…

Relapse/Refractory Paediatric B-ALL Case with CD19(−) Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment—Case Report

The case reported presents a rare CD19(−) phenotype shift of an acute lymphoblastic leukaemia clone during relapse/refractory ALL in a paediatric patient. We explore possible reasons for the promotion of CD19-negative cell selection, including discrete mutations and anti-CD19 treatment, which is gai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prażmo, Anna, Jawoszek, Patryk, Styka, Borys, Lejman, Monika, Zaucha-Prażmo, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487976/ https://www.ncbi.nlm.nih.gov/pubmed/37686126 http://dx.doi.org/10.3390/ijms241713322

Ejemplares similares

Diagnostic difficulties of AH1N1 influenza infection in children with acute lymphoblastic leukemia: Two case reports
por: Zawitkowska, Joanna, et al.
Publicado: (2020)

Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation
por: Lejman, Monika, et al.
Publicado: (2019)

Insight into the Molecular Basis Underlying Chromothripsis
por: Ostapińska, Katarzyna, et al.
Publicado: (2022)

Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?
por: Zaucha-Prażmo, Agnieszka, et al.
Publicado: (2016)

Case Report: Two Newly Diagnosed Patients With KBG Syndrome—Two Different Molecular Changes
por: Wojciechowska, Katarzyna, et al.
Publicado: (2021)

Risk Factors for Transplant Outcomes in Children and Adolescents with Non-Malignant Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
por: Zaucha-Prażmo, Agnieszka, et al.
Publicado: (2019)

Fertility Preservation in Children and Adolescents during Oncological Treatment—A Review of Healthcare System Factors and Attitudes of Patients and Their Caregivers
por: Pawłowski, Piotr, et al.
Publicado: (2023)

Effectiveness of repeated photodynamic therapy in the elimination of intracanal Enterococcus faecalis biofilm: an in vitro study
por: Prażmo, Ewa Joanna, et al.
Publicado: (2017)

First-line treatment failure in childhood acute lymphoblastic leukemia: The polish pediatric leukemia and lymphoma study group experience
por: Zawitkowska, Joanna, et al.
Publicado: (2020)

Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation
por: Czyzewski, Krzysztof, et al.
Publicado: (2019)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Kaczmarska, Agnieszka, et al.
Publicado: (2021)

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
por: Prejzner, Witold, et al.
Publicado: (2023)

P340: IN SEARCH FOR GENOMIC AND TRANSCRIPTOMIC PREDICTORS OF RELAPSE IN PEDIATRIC T-ALL
por: Dawidowska, Małgorzata, et al.
Publicado: (2023)

Advantages and Limitations of SNP Array in the Molecular Characterization of Pediatric T-Cell Acute Lymphoblastic Leukemia
por: Lejman, Monika, et al.
Publicado: (2020)

P387: THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL
por: Liu, Shuangyou, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
por: Di Palma, Martina, et al.
Publicado: (2022)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
por: Wróbel, Tomasz, et al.
Publicado: (2023)

Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL
por: Lejman, Monika, et al.
Publicado: (2020)

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)

Advanced Molecular Characterisation in Relapsed and Refractory Paediatric Acute Leukaemia, the Key for Personalised Medicine
por: Galán-Gómez, Víctor, et al.
Publicado: (2022)

The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia
por: Urbańska, Zuzanna, et al.
Publicado: (2022)

Genetic Disorders with Predisposition to Paediatric Haematopoietic Malignancies—A Review
por: Filipiuk, Aleksandra, et al.
Publicado: (2022)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: a nationwide study
por: Salamonowicz-Bodzioch, Małgorzata, et al.
Publicado: (2021)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund, Audrey M, et al.
Publicado: (2020)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium
por: White, Tara, et al.
Publicado: (2022)

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Statins: are they appropriate for all patients?
por: Raal, Frederick J, et al.
Publicado: (2022)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
por: Forsberg, Matthew H, et al.
Publicado: (2018)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Intrachromosomal Amplification of Chromosome 21 in Childhood Acute Lymphoblastic Leukemia: Study of 3 Cases
por: Mroczkowska, Aleksandra, et al.
Publicado: (2021)

Chromosomal instability associated with adverse outcome: a case report of patient with Nijmegen breakage syndrome and rapidly developed T-NHL with complex karyotype
por: Włodarczyk, Monika, et al.
Publicado: (2020)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1hck4tbdehtl3086qm0u9no30f